Amphiregulin is an essential mediator of estrogen receptor α function in mammary gland development

  1. Laura Ciarloni*,
  2. Sonia Mallepell*, and
  3. Cathrin Brisken*,,
  1. *Swiss Institute for Experimental Cancer Research, National Center of Competence in Research, Molecular Oncology, Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland; and
  2. Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland
  1. Communicated by Pierre Chambon, Mouse Clinical Institute and Institut de Génétique et de Biologie Moléculaire et Cellulaire, Strasbourg, France, December 28, 2006 (received for review December 15, 2006)

Abstract

Most mammary gland development occurs after birth under the control of systemic hormones. Estrogens induce mammary epithelial cell proliferation during puberty via epithelial estrogen receptor α (ERα) by a paracrine mechanism. Epidermal growth factor receptor (EGFR) signaling has long been implicated downstream of ERα signaling, and several EGFR ligands have been described as estrogen-target genes in tumor cell lines. Here, we show that amphiregulin is the unique EGF family member to be transcriptionally induced by estrogen in the mammary glands of puberal mice at a time of exponential expansion of the ductal system. In fact, we find that estrogens induce amphiregulin through the ERα and require amphiregulin to induce proliferation of the mammary epithelium. Like ERα, amphiregulin is required in the epithelium of puberal mice for epithelial proliferation, terminal end buds formation, and ductal elongation. Subsequent stages, such as side-branching and alveologenesis, are not affected. When amphiregulin−/− mammary epithelial cells are in close vicinity to wild-type cells, they proliferate and contribute to all cell compartments of the ductal outgrowth. Thus, amphiregulin is an important paracrine mediator of estrogen function specifically required for puberty-induced ductal elongation, but not for any earlier or later developmental stages.

Footnotes

  • To whom correspondence should be addressed. E-mail: cathrin.brisken{at}isrec.ch
  • Author contributions: L.C. and C.B. designed research; L.C. and S.M. performed research; L.C. and C.B. analyzed data; and C.B. wrote the paper.

  • The authors declare no conflict of interest.

  • Abbreviations:
    ER,
    estrogen receptor;
    TEBs,
    terminal end buds;
    TGF-α,
    transforming growth factor α;
    HB-EGF,
    heparin binding-EGF;
    BTC,
    betacellulin;
    EPR,
    epiregulin;
    EGFR,
    epidermal growth factor receptor;
    SMAα,
    smooth muscle actin α.
« Previous | Next Article »Table of Contents